journal article·2023-02-17Open access

Natural Compounds Isolated from African Mistletoes (Loranthaceae) Exert Anti-Inflammatory and Acetylcholinesterase Inhibitory Potentials: In Vitro and In Silico Studies

Emmanuel Mfotie Njoya, Hermine L. D. Maza, Shasank S. Swain, Chika. I. Chukwuma, Pierre Mkounga, Yves M. Nguekeu Mba, Samson S. Mashele, Tshepiso J. Makhafola, Lyndy J. McGaw

Applied Sciences· Volume 13· Issue 4

Abstract

Despite the medicinal uses of Phragmanthera capitata, Globimetula dinklagei and Tapinanthus bangwensis against memory loss, convulsions and pain, their efficacy against brain-dysfunction diseases and inflammation models has not yet been studied. Therefore, this study aims to investigate the anti-inflammatory and acetylcholinesterase (AChE) inhibitory potentials of their crude extracts and isolated natural compounds by combining in vitro and in silico experiments. Crude extracts and isolated compounds were tested in vitro for their AChE inhibitory activity by using Ellman’s method. Additionally, their anti-inflammatory activity was determined by evaluating the nitric oxide (NO) production inhibitory activity in lipopolysaccharide-stimulated RAW 264.7 macrophage cells and the 15-lipoxygenase (15-LOX) inhibitory activity by using the ferrous oxidation xylenol orange assay. Furthermore, the in silico efficacy of natural compounds was investigated against ten putative target enzymes relevant in Alzheimer’s disease (AD) pathogenesis and inflammation. It was found that the crude extracts had weak to moderate inhibitory potential against AChE, with the extract of T. bangwensis being the most active (50% inhibitory concentration (IC50) = 48.97 µg/mL). Six natural compounds, namely, 3-O-β-D-glucopyranosyl-28-hydroxy-α-amyrin (2), apigenin- 8-C-β-D-glucopyranoside (3), globimetulin B (5), globimetulin C (6), bangwaursene B (8) and 3β-acetoxy-11,12-epoxytaraxerol (9), were identified for the first time as having anti-AChE potential, among which (9) had the highest efficacy with an IC50 of 13.89 µM. Among the anti-AChE compounds, (5) was also efficient against NO production and 15-LOX, and the data are in agreement with the docking score. In summary, compounds (5) and (9) are the most prominent lead compounds that should be further tested experimentally against molecular targets of AD and inflammation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cholinesterase and Neurodegenerative Diseases · Allelopathy and phytotoxic interactions · Toxin Mechanisms and Immunotoxins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Quality of Health and Living, Faculty of Health and Environmental Sciences, Central University of Technology, Bloemfontein 9301, South Africa

Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, Pretoria 0110, South Africa

Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Yaoundé 812, Cameroon

Division of Microbiology & NCDs, ICMR-Regional Medical Research Centre, Bhubaneswar 751023, India

Funding

Central University of Technology · National Research Foundation

References (64)

Show source-provided references
1. African mistletoes (Loranthaceae); ethnopharmacology, chemistry and medicinal values: An update
2. Biology and resource acquisition of mistletoes, and the defense responses of host plants10.1186/s13717-021-00355-9 ↗
3. Cytotoxic and Hepatocurative Effect of Aqueous Fraction of Tapinanthus bangwensis Against Paracetamol-Induced Hepatotoxicity10.1177/2515690X18801577 ↗
4. Study on anti-diabetic activities of crude methanolic extracts of Loranthus micranthus (Linn.) sourced from five different host trees10.1016/j.jep.2004.06.029 ↗
5. An assessment on the uses of Loranthaceae in ethnopharmacology in Cameroon: A case study made in Logbessou, North of Douala
6. Antibacterial properties and preliminary phytochemical analysis of methanolic extract of mistletoe (Tapinanthus bangwensis)
7. Extrinsic Factors Influencing Antibacterial Activities of Tapinanthus bangwensis Against Diarrheal Causing Organisms
8. Biological activities and nutritional value of Tapinanthus bangwensis leaves10.5897/AJB12.1805 ↗
9. Antioxidant and inhibitory effects of aqueous and ethanolic extract of Tapinanthus bangwensis leaves on Fe2+-induced lipid peroxidation in pancreas (in vitro)
10. Antioxidant Activity of some Secondary metabolites from Tapinanthus bangwensis (Engl., and K. Krause) [Loranthaceae] Grown in Nigeria
11. Anti-Pyretic and Analgesic Potentials of Aqueous Extract of Phragmanthera capitata S. Balle in Albino Rats
12. Hepatoprotective effects of methanolic extract and fractions of African mistletoe Tapinanthus bangwensis (Engl. & K. Krause) from Nigeria
13. Steroidogenetic and Spermatogenetic Activities of Aqueous Extract of Phragmanthera capitata in Wistar Rats
14. Antihyperglycaemic and Antihyperproteinaemic Activity of Extracts of Picralima nitida Seed and Tapinanthus bangwensis Leaf on Alloxan-Induced Diabetic Rabbits
15. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro10.3389/fmicb.2015.00488 ↗
16. Evaluation of the Methanolic Extract of Mistletoe (Tapinanthus bangwensis) Leaves Grown on Orange Trees for the Phytochemical Properties and its Physiological: Effects on Streptozotocin Induced Diabetes mellitus in Laboratory Animals
17. Selective cytotoxic activity of isolated compounds from Globimetula dinklagei and Phragmanthera capitata (Loranthaceae)10.1515/znc-2019-0171 ↗
18. African mistletoe (Loranthaceae) enhances spatial and non-spatial working memory in hypercholesterolemia model of Alzheimer’s disease
19. Alzheimer’s disease10.1016/S0140-6736(15)01124-1 ↗
20. The cholinergic hypothesis of Alzheimer’s disease: A review of progress10.1136/jnnp.66.2.137 ↗
21. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development10.1124/jpet.102.041616 ↗
22. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease10.1016/j.neuropharm.2020.108352 ↗
23. Acetylcholinesterase inhibitors: Pharmacology and toxicology10.2174/1570159X11311030006 ↗
24. Trang, A., and Khandhar, P.B. (2022). Physiology, Acetylcholinesterase, StatPearls.
25. Chemical Compounds in Natural Medicines That Affect Macropharges and Adipocyte Cells10.1248/yakushi.16-00027 ↗
26. Nitric oxide and redox mechanisms in the immune response10.1189/jlb.1010550 ↗
27. Association of endothelial nitric oxide synthase and mitochondrial dysfunction in the hippocampus of scrapie-infected mice10.1002/hipo.20753 ↗
28. 12/15-lipoxygenase is increased in Alzheimer’s disease: Possible involvement in brain oxidative stress10.1016/S0002-9440(10)63724-8 ↗
29. The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease10.1016/j.tips.2015.01.005 ↗
30. The 12-15-lipoxygenase is a modulator of Alzheimer’s-related tau pathology in vivo10.1111/acel.12136 ↗
31. Inflammation in Alzheimer’s disease: Relevance to pathogenesis and therapy10.1186/alzrt24 ↗
32. Can we do better in developing new drugs for Alzheimer’s disease?10.1016/j.jalz.2009.09.002 ↗
33. Mehta, M., Adem, A., and Sabbagh, M. (2012). New acetylcholinesterase inhibitors for Alzheimer’s disease. Int. J. Alzheimer’s Dis.10.1155/2012/728983 ↗
34. Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25.10.3390/molecules25245789 ↗
35. Natural Therapeutics in Aid of Treating Alzheimer’s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders10.3389/fnins.2022.884345 ↗
36. In silico and in vitro: Identifying new drugs10.2174/138945008786949397 ↗
37. Alkaloids with cholinesterase inhibitory activities from the bulbs of Crinum x amabile Donn ex Ker Gawl10.1016/j.phytochem.2022.113473 ↗
38. Kores, K., Kolenc, Z., Furlan, V., and Bren, U. (2022). Inverse Molecular Docking Elucidating the Anticarcinogenic Potential of the Hop Natural Product Xanthohumol and Its Metabolites. Foods, 11.10.3390/foods11091253 ↗
39. Pantiora, P., Furlan, V., Matiadis, D., Mavroidi, B., Perperopoulou, F., Papageorgiou, A.C., Sagnou, M., Bren, U., Pelecanou, M., and Labrou, N.E. (2022). Monocarbonyl Curcumin Analogues as Potent Inhibitors against Human Glutathione Transferase P1-1. Antioxidants, 12.10.3390/antiox12010063 ↗
40. Steroids and triterpenoids from Eastern Nigeria mistletoe, Loranthus micranthus Linn. (Loranthaceae) parasitic on Kola acuminata with immunomodulatory potentials
41. New Triterpenoid Glycosides from Taverniera Aegyptiaca Boiss
42. Isolation and identification of 8-C- galactosyl apigenine from leaves of Carlina ancathifolia10.1002/hlca.19830660804 ↗
43. New Lupan-Type Triterpenoid Derivatives from Globimetula dinklagei (Loranthaceae) Hemiparasitic Plant Growing on Manihot esculenta (Euphorbiaceae)
44. Triterpenoids from seeds of Tapinanthus bangwensis10.1016/j.phytol.2016.11.002 ↗
45. Three new pentacyclic triterpenes and some flavonoids from the fruits of an Indian Ayurvedic plant Dendrophthoe falcata and their estrogen receptor binding activity10.1248/cpb.54.740 ↗
46. A new and rapid colorimetric determination of acetylcholinesterase activity10.1016/0006-2952(61)90145-9 ↗
47. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗
48. Determination of lipoxygenase activity in plant extracts using a modified ferrous oxidation-xylenol orange assay10.1021/jf070537x ↗
49. Inhibition of Nitric Oxide Production in LPS-Stimulated RAW 264.7 Macrophages and 15-LOX Activity by Anthraquinones from Pentas schimperi10.1055/s-0042-104417 ↗
50. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: A molecular docking-simulation base assessment10.1080/07391102.2021.1885495 ↗
51. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro10.1002/prot.26341 ↗
52. Zinc(II)—Syringic acid complexation synergistically exerts antioxidant action and modulates glucose uptake and utilization in L-6 myotubes and rat muscle tissue10.1016/j.biopha.2022.113600 ↗
53. Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation10.1016/j.ejmech.2022.114173 ↗
54. Acetylcholinesterase inhibitors from plants10.1016/j.phymed.2007.02.002 ↗
55. Acetylcholinesterase inhibitors of natural origin
56. Acetylcholinesterase inhibitor from Clitoria ternatea10.1055/s-2007-987259 ↗
57. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel10.1007/BF02980046 ↗
58. Natural AChE Inhibitors from Plants and their Contribution to Alzheimer’s Disease Therapy10.2174/1570159X11311040004 ↗
59. The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease10.1007/s11064-015-1776-x ↗
60. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment10.1002/ana.20558 ↗
61. Arachidonate 12-lipoxygenases10.1016/S0090-6980(02)00034-5 ↗
62. Lipoxygenase inhibitors from natural plant sources. Part 2: Medicinal plants with inhibitory activity on arachidonate 12-lipoxygenase, 15-lipoxygenase and leukotriene receptor antagonists10.1002/ptr.1604 ↗
63. Rational Development of a Potent 15-Lipoxygenase-1 Inhibitor with in Vitro and ex Vivo Anti-inflammatory Properties10.1021/acs.jmedchem.5b01121 ↗
64. Developments with multi-target drugs for Alzheimer’s disease: An overview of the current discovery approaches10.1080/17460441.2019.1623201 ↗